Last reviewed · How we verify
Azacitidine combined to Lenalidomide
Azacitidine and lenalidomide work together to restore normal gene expression in myelodysplastic syndrome cells through DNA methylation inhibition and immunomodulation.
Azacitidine and lenalidomide work together to restore normal gene expression in myelodysplastic syndrome cells through DNA methylation inhibition and immunomodulation. Used for Myelodysplastic syndrome (MDS), including higher-risk MDS.
At a glance
| Generic name | Azacitidine combined to Lenalidomide |
|---|---|
| Also known as | Vidaza., Revlimid. |
| Sponsor | Groupe Francophone des Myelodysplasies |
| Drug class | Hypomethylating agent + Immunomodulatory agent combination |
| Target | DNA methyltransferase (azacitidine); cereblon/CRBN (lenalidomide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Azacitidine is a hypomethylating agent that inhibits DNA methyltransferase, reversing aberrant DNA methylation and reactivating silenced tumor suppressor genes. Lenalidomide is an immunomodulatory drug that enhances T-cell proliferation and NK cell activity while promoting degradation of specific proteins. The combination targets both the epigenetic abnormalities and immune dysfunction characteristic of myelodysplastic syndromes.
Approved indications
- Myelodysplastic syndrome (MDS), including higher-risk MDS
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Fatigue
- Nausea and vomiting
- Diarrhea
- Thromboembolism (lenalidomide-related)
Key clinical trials
- Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (PHASE2)
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies (PHASE1, PHASE2)
- Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (PHASE2)
- Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (PHASE1, PHASE2)
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma (PHASE1)
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (PHASE2)
- Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS (PHASE4)
- Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |